Halozyme Therapeutics

Yahoo Finance • yesterday

Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory

We came across a bullish thesis on Halozyme Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on HALO. Halozyme Therapeutics, Inc.'s share was trading at $70.98 as of February 20th. HALO’s... Full story

Yahoo Finance • 4 days ago

2 Reasons to Like HALO (and 1 Not So Much)

Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that period. Is now the time to buy HALO? Or do... Full story

Yahoo Finance • 10 days ago

Halozyme (HALO) Loses 9% on Weak Earnings

We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday. Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent... Full story

Yahoo Finance • 12 days ago

Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...

This article first appeared on GuruFocus. Total Revenue: $1.4 billion, a 38% increase year-over-year. Royalty Revenue: $867.8 million, a 52% increase year-over-year. Net Income: $316.9 million, compared to $444.1 million in 2024. Adjusted... Full story

Yahoo Finance • 12 days ago

Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline

Earnings Call Insights: Halozyme Therapeutics (HALO) Q4 2025 MANAGEMENT VIEW * Helen Torley, President and CEO, highlighted that "2025 was one of the most significant and value-creating years in Halozyme's history," citing the expansio... Full story

Yahoo Finance • 12 days ago

Halozyme (HALO) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Date Feb. 17, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Helen I. TorleyChief Scientific Officer — Chris WallChief Financial Officer — Nicole LaBrosse Takeaways Total revenue -- $1... Full story

Yahoo Finance • 12 days ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration T... Full story

Yahoo Finance • 13 days ago

Halozyme Therapeutics Q4 2025 Earnings Preview

* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) is scheduled to announce Q4 earnings results on Tuesday, February 17th, after market close. * The consensus EPS Estimate is $2.20 [https://seekingalpha.com/symbol/HA... Full story

Yahoo Finance • 24 days ago

This Medical Technology Leader Sees Growth Into The 2040s

Medical technology leader Halozyme Therapeutics is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outl... Full story

Yahoo Finance • 25 days ago

Dow Jones Leader Cisco, Halozyme, Toll Brothers In Or Near Buy Zones

Dow Jones leader Cisco Systems, along with Halozyme, Toll Brothers, and Quanta Services, are in or near buy zones Wednesday. Continue Reading... Full story

Yahoo Finance • 2 months ago

Here’s What Analysts Think About Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Fo... Full story

Yahoo Finance • 2 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 2 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received appro... Full story

Yahoo Finance • 3 months ago

Toast upgraded, PayPal downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premiu... Full story

Yahoo Finance • 3 months ago

Stocks Settle Mixed on Higher Bond Yields

The S&P 500 Index ($SPX) (SPY) on Thursday closed up by +0.11%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down by -0.07%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down by -0.10%.  December E-mini S&P futures (ESZ25) rose +0... Full story

Yahoo Finance • 3 months ago

Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda

Alexander Sikov * A court in Munich has granted a preliminary injunction to Halozyme (HALO [https://seekingalpha.com/symbol/HALO]) that prevents Merck (MRK [https://seekingalpha.com/symbol/MRK]) from distributing the subcutaneous versio... Full story

Yahoo Finance • 3 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offerin... Full story

Yahoo Finance • 3 months ago

Stocks Pressured as Bond Yields Rise and Chip Stocks Fall

The S&P 500 Index ($SPX) (SPY) is down by -0.06%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.28%.  December E-mini S&P futures (ESZ25) are down -0.07%, and December... Full story

Yahoo Finance • 3 months ago

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) Following Appreciation

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains... Full story

Yahoo Finance • 3 months ago

This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why

We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme T... Full story